Evonik, a prominent player in the chemical industry, is making noteworthy strides in its DL-methionine production plant expansion located in Singapore. To achieve a crucial milestone in the construction process, the production at the Singapore plant on Jurong Island will experience a temporary reduction for three months in the fourth quarter of 2023. Following this, there will be another three-month tie-in shutdown in the first half of 2024.
This strategic shutdown is an integral part of Evonik’s methionine asset strategy, aimed at securing long-term global supply reliability. As the expansion progresses as planned, the scheduled production stops in Q4FY23 and H1FY24, primarily for maintenance and safety purposes, will allow essential modifications to be undertaken, which would not be feasible during regular day-to-day operations.
Noel Kim, the regional vice president of Animal Nutrition, emphasized that while they understand the potential challenges these shutdowns may pose for customers, the company’s teams have devised mitigation plans to ensure a steady supply of MetAMINO® from their global production network. Evonik is in constant communication with both regional and global customers to carefully plan shipments during this period.
Earlier this year, Evonik disclosed a substantial investment in the range of high double-digit million euros. This investment aims to augment the production capacity of MetAMINO® (DL-methionine) on Jurong Island, Singapore, by an impressive 40,000 metric tons per year, bringing the total production to approximately 340,000 metric tons per year. This expansion not only enhances the facility’s operational efficiency but also contributes to a commendable 6% reduction in the carbon footprint of all Evonik’s MetAMINO® production in Singapore.